Lexeo Therapeutics (LXEO) Preferred Stock Liabilities (2022 - 2023)
Lexeo Therapeutics (LXEO) posted Preferred Stock Liabilities of $85.3 million for Q3 2023, down 53.92% sequentially from $185.0 million in Q2 2023, and down 53.92% YoY from $185.0 million in Q3 2022.
Powered by 
Analysis
Lexeo Therapeutics (LXEO) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends
Lexeo Therapeutics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $85.3 million in Q3 2023.
- Quarterly Preferred Stock Liabilities fell 53.92% year-over-year to $85.3 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $85.3 million (down 53.92% YoY) and the FY2022 annual result came in at $185.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities fell to $85.3 million in Q3 2023 per LXEO's latest filing, from $185.0 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $185.0 million in Q3 2022 and troughed at $85.3 million in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Lexeo Therapeutics | 419.14 Mn | 419.14 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 185.03 Mn |
| Jun 30, 2023 | 185.03 Mn |
| Mar 31, 2023 | 185.03 Mn |
| Dec 31, 2022 | 185.03 Mn |
| Sep 30, 2022 | 185.03 Mn |